Hikma Pharmaceuticals Plc Stock Current Liabilities
| HKMPF Stock | USD 24.47 1.91 8.47% |
Hikma Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Hikma Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Hikma Pink Sheet. The fundamental analysis module provides a way to measure Hikma Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hikma Pharmaceuticals pink sheet.
Hikma |
Hikma Pharmaceuticals PLC Company Current Liabilities Analysis
Hikma Pharmaceuticals' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Hikma Pharmaceuticals Current Liabilities | 592 M |
Most of Hikma Pharmaceuticals' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hikma Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Hikma Pharmaceuticals PLC has a Current Liabilities of 592 M. This is 66.22% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current liabilities for all United States stocks is 92.51% higher than that of the company.
Hikma Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hikma Pharmaceuticals' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hikma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Hikma Pharmaceuticals by comparing valuation metrics of similar companies.Hikma Pharmaceuticals is currently under evaluation in current liabilities category among its peers.
Hikma Fundamentals
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 5.26 B | |||
| Shares Outstanding | 220.26 M | |||
| Shares Owned By Insiders | 29.67 % | |||
| Shares Owned By Institutions | 41.69 % | |||
| Price To Earning | 7.89 X | |||
| Price To Book | 1.84 X | |||
| Price To Sales | 1.63 X | |||
| Revenue | 2.55 B | |||
| Gross Profit | 1.3 B | |||
| EBITDA | 758 M | |||
| Net Income | 421 M | |||
| Cash And Equivalents | 393 M | |||
| Cash Per Share | 1.78 X | |||
| Total Debt | 651 M | |||
| Debt To Equity | 0.71 % | |||
| Current Ratio | 2.12 X | |||
| Book Value Per Share | 9.89 X | |||
| Cash Flow From Operations | 638 M | |||
| Earnings Per Share | 1.50 X | |||
| Price To Earnings To Growth | 2.35 X | |||
| Number Of Employees | 8.7 K | |||
| Beta | 0.35 | |||
| Market Capitalization | 4.6 B | |||
| Total Asset | 4.37 B | |||
| Retained Earnings | 1.16 B | |||
| Working Capital | 768 M | |||
| Current Asset | 1.36 B | |||
| Current Liabilities | 592 M | |||
| Z Score | 4.2 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 1.80 % | |||
| Net Asset | 4.37 B | |||
| Last Dividend Paid | 0.55 |
About Hikma Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hikma Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hikma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hikma Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Hikma Pink Sheet
Hikma Pharmaceuticals financial ratios help investors to determine whether Hikma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hikma with respect to the benefits of owning Hikma Pharmaceuticals security.